Clinical Trial Update: An Open-Label Study of Apabetalone in Covid Infection [Phase 2, Phase 3]

View source ↗

Summary

Open-label study of apabetalone in COVID-19 infection was terminated after Phase 2/3; no conclusive results reported here.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Infection

Drugs mentioned

• apabetalone (apabetalone)

Snippet

Sponsor: Resverlogix Corp | Conditions: COVID-19 Infection | Phase 2, Phase 3 | Status: TERMINATED